LATE-BREAKING ABSTRACT: Simtuzumab in idiopathic pulmonary fibrosis: Results of a randomized clinical trial
Thomas O'Riordan (Seattle, United States of America), Ganesh Raghu, Kevin Brown, Harold Collard, David Lederer, Fernando Martinez, Paul Noble, Jin Woo Song, Athol Wells, Timothy Whelan, Emmanuel Moreau, Scott Patterson, Selina Bayly, Jason Chien, Jennifer Zhang, Thomas O’Riordan
|   |
Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials
Paul Noble (Los Angeles, United States of America), Paul Noble, Carlo Albera, Lisa Lancaster, Phillip Hormel, Henry Hulter, Ulrich Costabel
|  |
Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Paul Noble (Los Angeles, United States of America), Paul Noble, Carlo Albera, Klaus-Uwe Kirchgaessler, Frank Gilberg, Ute Petzinger, Ulrich Costabel
| |
Annual rate of FVC decline in patients with IPF treated with pirfenidone: Pooled analysis from 3 pivotal studies
Paul Noble (Los Angeles, United States of America), Paul Noble, Carlo Albera, Willis Chou, Ulrich Costabel, Bann-mo Day, Ian Glaspole, Marilyn Glassberg, Lisa Lancaster, David Lederer, Steven Nathan, Carlos Pereira, John Stauffer, Jeffrey Swigris
| |
Effect of baseline composite physiologic index on benefit of nintedanib in IPF
Athol Wells (London, United Kingdom), Athol Wells, Jürgen Behr, Wibke Stansen, Susanne Stowasser, Toby Maher
| |
Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF)
Ulrich Costabel (Essen, Germany), Ulrich Costabel, Carlo Albera, Lisa Lancaster, Phillip Hormel, Henry Hulter, Paul Noble
| |
Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP
Ulrich Costabel (Essen, Germany), Ulrich Costabel, Carlo Albera, Klaus-Uwe Kirchgaessler, Frank Gilberg, Ute Petzinger, Paul Noble
| |
Twenty-four week decline in forced vital capacity predicts mortality at week 52 in the INPULSIS® trials
Luca Richeldi (Southampton, United Kingdom), Luca Richeldi, Arata Azuma, Moisés Selman, Wenbo Tang, Jorge Capapey, Susanne Stowasser, Vincent Cottin
| |